Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« We Now Return to Our Regularly Scheduled Program | Main | System Biology: Ready, or Not? »

November 6, 2008

CB-1 Obesity Drugs: Farewell to the Whole Lot

Email This Entry

Posted by Derek

The painful saga of Acomplia (rimonabant) has finally come to an end. Sanofi-Aventis has announced that they're completely giving up on the drug. There was really no other option - the compound was never approved in the US, and was never going to be, and late in October the EU ordered it to be withdrawn from Europe. The psychiatric side effects which sank the drug's chances here were showing up in real-world use, and the risk/benefit ratio could no longer be seen as anything but negative.

And Pfizer has just announced that they're giving up work on their own Phase III compound in the area, CP-945,598. They're not citing safety concerns - and as Jim Edwards over at Bnet notes, that puts them in the odd position of saying that they have a safe, effective drug for a huge market that they're not going to do anything with. My guess is that the company is worried that the drug would indeed show an unfavorable safety profile, especially under the sort of scrutiny that any drug in this class would have by now, and that they decided to stop before things got to that point. Otherwise, you'd think that a big, safe, effective first-in-class obesity therapy would be just what Pfizer needs - wouldn't you?

So, goodbye to the CB-1 antagonists. I don't see much work going on in this area for some time to come, unless the pharmacology gets untangled to the point that someone can see a safe way through. There may well not be one.

And before we all try to forget that this all happened, let's spare a thought for the huge amounts of time, effort, brainpower and money that went into this area over the last eight or ten years. Three of the biggest research organizations in the industry have now flamed out trying to develop these drugs, and plenty of smaller players were trying, too, as a glance at the patent literature will make clear. The end result is that we have paid a gigantic amount of money to learn that the biology is more complicated than we thought, and it needed no ghost come from the grave to tell us this. If you think that drug development is a sure road to riches - if anyone still thinks that - then come survey this wreckage and think again.

And to finish, let's hop in the time machine and go back. . .well, not all that far. Just to mid-2006. There we find a world in which rimonabant was poised to become one of the biggest selling drugs in all the world, part of a wave of drugs which would transform the industry and spew profits in all directions. Billions of dollars in revenues are mentioned. Oh, dear.

Comments (17) + TrackBacks (0) | Category: Diabetes and Obesity | Drug Development


COMMENTS

1. Jose on November 6, 2008 9:39 AM writes...

Priceless!

"It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small market, into a gold mine for the pharmaceutical industry."

Permalink to Comment

2. Jonathan on November 6, 2008 9:47 AM writes...

I'm still a little surprised they never saw any vascular side effects in addition to the neuro ones.

Permalink to Comment

3. RB Woodweird on November 6, 2008 12:56 PM writes...

Failure? What failure? These anti-obesity drugs took grossly fat profit projections and slimmed them down to emaciated supermodel-cadaverous size.

Permalink to Comment

4. T on November 7, 2008 11:29 AM writes...

Isn't this somewhat analogous to the PPAR drugs? Potential blockbusters for an ever-expanding market - some drugs withdrawn - troubling side-effects and whatnot leading to problems with the class? I remember not too long ago PPARs seemed all the rage.

Permalink to Comment

5. leigh on November 8, 2008 3:00 PM writes...

i attended a very good talk on the complications of cannabinoid based drugs in industry (for academics) that explained very concisely what is so painful about these major drug losses. it was much in line with the basics of drug development class i took several years ago but with numbers to indicate how completely screwed companies are. really, amazingly painful numbers. the simple fact that cb1 is so freaking ubiquitous in the brain should be enough to scream "potential side effects" if you ask me. i guess my focus in the field won't be quite so useful when i graduate!

Permalink to Comment

6. ThomasD on November 9, 2008 3:49 PM writes...

the simple fact that cb1 is so freaking ubiquitous in the brain should be enough to scream "potential side effects" if you ask me.

Potential adverse effects does not always mean product destroyer. But it is one of the reasons we do so much testing. Another ubiquitous neurotransmitters? Dopamine. Any guess how many drugs with significant dopaminergic activity are currently on the market?

But the current situation isn't so much a risk vs. benefit type of analysis, it's a liability vs. profitability analysis.

Given the endemic nature of obesity and type II diabetes - with all its associated morbidity and mortality the nuerologic effects of such agents, although marked, may not be unacceptable when weighed against the alternative costs. Of course compared to losing weight in a 'healthy way' most any pharmacologic intervention is going to look like a bad idea.

Permalink to Comment

7. lennyjoels on November 9, 2008 6:29 PM writes...

I'm disappointed that rimonabant or other CB1 antagonists will not be coming to market in the US. I have many morbidly obese patients who have failed diets and counseling and the alternative would be bariatric surgery. Effective bariatric surgery (gastric bypass) has at least a 0.2% mortality rate and a 40% complication rate. Surely rimonabant would be safer than that.

It seems that pharmaceuticals are held to higher standards than surgical techniques.

Permalink to Comment

8. Mack on November 10, 2008 1:34 AM writes...

While looking for alternatives to SSRI's for a friend of mine who had an adverse reaction I came across an internet site www.neuroassist.com which appears to be a physician run organisation that doesn't deal with the general public and hosts AMA courses to train other doctors and clinics in the use of the amino acid precursors for serotonin and dopamine (5-HTP and L-Tyrosine). It's principal Dr. Hinze, appears to be working in conjunction with the University of Minnesota Medical School.

It claims that use of its protocols achieve impressive results in patients for an astonishingly wide selection of ailments, including obesity.

Without going into the bona fides, claims, testimonials from doctors using the protocols etc, I am curious to know if others are of the opinion that the hunger that drives morbid obesity could be driven by a deficiency of neurotransmitters (or a failure to effectively utilise neurotransmitters in the body) and could thus be treated with no side effects by the amino acid therapy and protocols of the kind promoted on the site.

And just so you know, I have no affiliation with this company. They are based in the US, don't have any practitioners in Australia as far as I am aware and don't respond to any inquiries unless they are from a licensed medical practitioner.

Permalink to Comment